Maine PointeResults. Now.™

Capacity and compliance together: pharma operations that scale

Measure capacity through testing and release before adding equipment, shifts or inventory that the rest of the system cannot absorb.

Stephen Ottley · Senior Advisor, Industry & TransformationLinkedIn profile ↗
6 min read

The production line finishes more batches, but customers still wait. Work accumulates in testing, documentation review or deviation investigation. Inventory rises, delivery remains uncertain and another shift starts to look necessary. This is not always a manufacturing-capacity problem. It is often a mismatch between the rate at which the plant creates work and the rate at which the complete system can deliver released, usable product.

Define capacity at the point of usable output

Rated equipment capacity is useful for engineering, but it is not a supply commitment. A pharmaceutical batch must complete the required manufacturing, testing, review and authorized disposition steps. Market eligibility and remaining shelf life can further constrain usability. Capacity planning should therefore follow the product through these dependencies rather than stop when equipment becomes available for the next batch.

Build a shared baseline of queues and processing time. Separate the time work is actively being performed from the time it waits for samples, information, review or a decision. Avoid a single average that hides different product pathways. A stable routine batch and a batch with an unresolved investigation impose different demands. Leaders need to understand that mix before deciding whether staffing or equipment is the limiting resource.

Balance the workload before increasing the rate

Campaign choices affect more than line efficiency. Longer campaigns may reduce changeovers while creating laboratory peaks, inventory exposure or an uneven release workload. A schedule that maximizes manufacturing utilization can overload the next function. Integrated planning should make those effects visible, allowing operations and quality to agree an executable sequence rather than passing a larger queue downstream.

  • Translate the manufacturing schedule into expected sampling and testing demand.
  • Check documentation readiness before the batch reaches review.
  • Reserve capacity for investigations and other variable quality work.
  • Coordinate maintenance and staffing with the actual product sequence.
  • Evaluate proposed output increases against released-product demand and shelf life.

The financial opportunity can extend beyond direct labor. Less waiting may reduce work in process and improve delivery predictability, while fewer avoidable handoff errors can reduce rework. These are opportunities to validate, not automatic benefits. In Maine Pointe's pharmaceutical case study, the published results report an achieved profitability improvement, with a scope spanning procurement, planning and logistics.

10%
profitability improvement

Make compliance part of operating design

Compliance and throughput become opponents when a change is designed first and quality is asked to approve it afterward. Bring quality and regulatory expertise into the problem definition. Specify which controls must remain intact, which proposed changes require formal assessment and what evidence will establish that the new process performs as intended. The aim is better execution inside the control framework, not a shortcut around it.

Useful improvements can be operationally straightforward: clearer documentation ownership, complete information at handoff, better alignment of sampling with laboratory availability and earlier escalation of missing records. Each site must assess changes through its applicable procedures. Equally, do not let an undefined appeal to compliance prevent examination of avoidable waiting or unclear responsibilities.

AI can support pattern recognition without taking over quality decisions. Maine Pointe's Combined Intelligence model is human-led, AI-enabled. It can help organize batch milestones and recurring delay narratives so leaders can investigate likely constraints. Maine Pointe Atlas can support retrieval of approved operating knowledge. Authorized process owners validate recommendations, and the appropriate quality authority retains control of disposition and required approvals.

What to do next: follow a batch to release

Select a representative product pathway and follow actual batches from scheduling through release. Record waiting, missing information, repeated handling and escalation delays. Bring manufacturing, laboratories, quality and planning together to test the explanation. Then choose a manageable improvement whose effect can be observed without changing several assumptions at once. Measure released output and queue behavior, not just the local activity that became faster.

The Pharmaceutical Value Assessment establishes this released-capacity baseline alongside supply exposure and inventory economics. It turns findings into a governed roadmap with accountable owners and quality decision gates. Add equipment when equipment is the constraint. Add shifts when the complete system can support them. Scale the ability to supply, not merely the ability to manufacture.

Stephen Ottley, Senior Advisor, Industry & Transformation
Author
Stephen Ottley
Senior Advisor, Industry & Transformation — Maine Pointe
LinkedIn profile ↗
Talk to our team →

Facing this in your business?

Tell us what you're trying to fix. A partner who has done it before will come back to you.

Talk to a partner